Quantcast

Evotec and Debiopharm Group(TM) to Collaborate on Development of New Treatment for Cancer

April 2, 2014

LAUSANNE, Switzerland and HAMBURG, Germany, April 2, 2014 /PRNewswire/ –

        - Innovative partnership based on Evotec's Target X projects
        - Evotec and Debiopharm to share discovery and development efforts

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today
a research collaboration and licensing deal with Debiopharm Group(TM), Lausanne,
Switzerland. The objective of this collaboration is to identify and develop novel
compounds having the potential to treat multiple forms of solid tumors and leukemias with
defined genetic alterations. Discovery and pre-clinical development efforts will be driven
by Evotec, whilst Debiopharm will manage clinical development. Evotec will receive R&D
funding and high double-digit total payments triggered by clinical, regulatory and
commercial milestones, plus royalties on sales of resulting commercial products.

This program is based on Evotec’s drug discovery efforts to investigate genetically
altered targets whose ‘driver’ role in several cancer types has been validated and on the
shared objective of identifying novel therapeutic agents in a variety of cancers,
including AML (Acute Myeloid Leukemia), prostate cancer and glioblastoma. Evotec is in the
unique position of being able to apply a broad range of highly sophisticated drug
discovery tools including state-of-the-art mass spectrometry and structure-based drug
design for rapid and efficient development of highly promising lead series. Debiopharm is
experienced in taking to maturity promising early stage biological or small molecule drug
candidates from preclinical to clinical development phase I, II and III, including
subsequent out-licensing to pharmaceutical partners for sales and marketing.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “We are very excited
about this innovative collaboration structure between Debiopharm and Evotec. It combines
our proven discovery platform with Debiopharm’s ability to advance projects through
clinical development in a highly efficient manner while sharing risks and rewards of
Evotec’s TargetX project. There is compelling science around the target and we are
confident that we will be able to position highly competitive compounds in this field that
hold great potential for difficult to treat cancers.”

“This is a fine example of how drug discovery and development will be in the future: a
mixture of complementarities looking to bring to a defined population of patients a drug
that will change the outcome of disease” added Andres McAllister, Chief Scientific
Officer, Debiopharm International SA.”

“Through this collaboration with Evotec, Debiopharm is strengthening its position in
early projects with a leader in the drug discovery field” said Thierry Mauvernay, Delegate
of the Board of Debiopharm Group “. Furthermore, this R&D program targeting cancers with
known genetic alterations is a whole part of our strategy for personalized medicines”.

About Debiopharm Group(TM)

Debiopharm Group(TM) is a Swiss-based global biopharmaceutical group of four companies
active in drug development, GMP manufacturing of proprietary drugs, diagnostics, and
investments.

Debiopharm International SA is focused on the development of prescription drugs that
target unmet medical needs. The company in-licenses, develops and/or co-develops promising
biological and small molecule drug candidates for global registration. The products are
commercialized through out-licensing to pharmaceutical partners to give access to the
largest number of patients worldwide. For more information about Debiopharm Group(TM),
please visit: http://www.debiopharm.com

About EVOTEC AG

Evotec is a drug discovery alliance and development partnership company focused on
rapidly progressing innovative product approaches with leading pharmaceutical and
biotechnology companies. We operate worldwide providing the highest quality stand-alone
and integrated drug discovery solutions, covering all activities from target-to-clinic.
The Company has established a unique position by assembling top-class scientific experts
and integrating state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as
well as oncology and inflammation. Evotec has long-term discovery alliances with partners
including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals,
MedImmune/AstraZeneca and Ono Pharmaceutical. In addition, the Company has existing
development partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim, MedImmune and Andromeda
in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with
Roche in the field of Alzheimer’s disease. For additional information please go to

http://www.evotec.com.

Forward Looking Statements: Information set forth in this press release contains
forward-looking statements, which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement of Evotec as of the
date of this report. Such forward-looking statements are neither promises nor guarantees,
but are subject to a variety of risks and uncertainties, many of which are beyond our
control, and which could cause actual results to differ materially from those contemplated
in these forward-looking statements. We expressly disclaim any obligation or undertaking
to release publicly any updates or revisions to any such statements to reflect any change
in our expectations or any change in events, conditions or circumstances on which any such
statement is based.

        Debiopharm International SA Contact
        Christelle Tur
        Communication Coordinator
        christelle.tur@debiopharm.com
        Tel.: +41(0)21-321-01-11

        Evotec AG Contact
        Gabriele Hansen
        Head of Corporate Communications
        gabriele.hansen@evotec.com
        Tel.: +49(0)40-560-81-255
        Fax: +49(0)40-560-81-222

        Additional Media Contacts
        In London
        Maitland
        Brian Hudspith
        bhudspith@maitland.co.uk
        Tel.: +44(0)20-7379-5151

        In New York
        Russo Partners, LLC
        Martina Schwarzkopf, Ph.D.
        Account Executive
        martina.schwarzkopf@russopartnersllc.com
        Tel.: +1-212-845-4292

SOURCE Debiopharm Group


Source: PR Newswire



comments powered by Disqus